Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae

被引:47
作者
Licata, L [1 ]
Smith, CE [1 ]
Goldschmidt, RM [1 ]
Barrett, JF [1 ]
Frosco, M [1 ]
机构
[1] RW JOHNSON PHARMACEUT RES INST,DEPT MICROBIOL,RARITAN,NJ 08869
关键词
D O I
10.1128/AAC.41.5.950
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The postantiobiotic subminimum inhibitory concentration effect (PA SME) may simulate in vivo drug exposure more accurately than the postantibiotic effect (PAE) since subinhibitory concentrations of drug persist between antibiotic dosings. In this study, we compared the PAEs and PA SMEs of levofloxacin and ciprofloxacin for clinical isolates of fluoroquinolone-susceptible Staphylococcus aureus and Streptococcus pneumoniae. At two times the MIC, PAEs of levofloxacin were an average of 0.6 h longer than the PAEs obtained for ciprofloxacin for methicillin-susceptible and methicillin-resistant S. aureus strains. The PAEs of levofloxacin and ciprofloxacin ranged from 1.8 to 3.1 and 1.1 to 2.4 h, respectively. Continued exposure of the methicillin-resistant strain to 1/16, 1/8, and 1/4 the MIC resulted in PA SMEs of 6.5, 15.3, and >22.3 h, respectively, for levofloxacin and 3.8, 8.0, and 12.3 h, respectively, for ciprofloxacin. For isolates of S. pneumoniae, at two times the MIC of both fluoroquinolones, the average PAEs of levofloxacin and ciprofloxacin were equivalent: 1.3 h for the penicillin-susceptible isolate and 0.6 h for the penicillin-resistant isolate. Continued exposure of the penicillin-susceptible S. pneumoniae strain to 1/16, 1/8, and 1/4 the MIC resulted in average PA SMEs of 1.0, 1.4, and 2.8 h, respectively, for levofloxacin and 1.8, 2.0, and 2.5 h, respectively, for ciprofloxacin. Continued exposure of penicillin-resistant S. pneumoniae to 1/16, 1/8, and 1/4 the MIC of the same fluoroquinolones resulted in average PA SMEs of 0.6, 1.1, and 2.9 h, respectively, for levofloxacin and 0.6, 1.1, and 1.5 h respectively, for ciprofloxacin. The PA SMEs observed demonstrate the superior activity of levofloxacin against methicillin-susceptible or methicillin-resistant S. aureus. Although PAEs were similar for the penicillin-susceptible and pencillin-resistant S. pneumoniae strains, the PA SME of levofloxacin at one-fourth the MIC was longer for penicillin-resistant S. pneumoniae.
引用
收藏
页码:950 / 955
页数:6
相关论文
共 27 条
[1]   PENICILLIN THERAPY WITH PROLONGED INTERVAL DOSAGE SCHEDULES [J].
ALTEMEIER, WA .
ANNALS OF SURGERY, 1948, 128 (04) :708-713
[2]   THE POSTANTIBIOTIC SUB-MIC EFFECT INVITRO AND INVIVO [J].
CARS, O ;
ODENHOLTTORNQVIST, I .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 :159-166
[3]  
Craig W.A., 1991, Antibiotics in Laboratory Medicine, V3rd ed., P403
[4]   INVITRO AND INVIVO ANTIBACTERIAL ACTIVITIES OF LEVOFLOXACIN (L-OFLOXACIN), AN OPTICALLY-ACTIVE OFLOXACIN [J].
FU, KP ;
LAFREDO, SC ;
FOLENO, B ;
ISAACSON, DM ;
BARRETT, JF ;
TOBIA, AJ ;
ROSENTHALE, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) :860-866
[5]   THE POSTANTIBIOTIC SUPPRESSIVE EFFECT OF L-OFLOXACIN, AN OPTICALLY-ACTIVE ISOMER OF OFLOXACIN [J].
FU, KP ;
FOLENO, B ;
ROSENTHALE, ME .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (04) :375-378
[6]   DIFFERENT PATTERNS OF BACTERIAL-DNA SYNTHESIS DURING POSTANTIBIOTIC EFFECT [J].
GOTTFREDSSON, M ;
ERLENDSDOTTIR, H ;
GUDMUNDSSON, A ;
GUDMUNDSSON, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1314-1319
[7]   POSTANTIBIOTIC EFFECT OF DU-6859A AND LEVOFLOXACIN AS COMPARED WITH OFLOXACIN [J].
HOUSTON, AK ;
JONES, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 18 (01) :57-59
[8]   POSTANTIBIOTIC EFFECTS OF OFLOXACIN ON ESCHERICHIA-COLI, KLEBSIELLA-PNEUMONIAE, STAPHYLOCOCCUS-AUREUS, AND STREPTOCOCCUS-PYOGENES [J].
HOWARD, BMA ;
PINNEY, RJ ;
SMITH, JT .
CHEMOTHERAPY, 1993, 39 (04) :265-271
[9]   CONTRIBUTIONS OF POSTANTIBIOTIC LAG AND REPAIR-RECOVERY TO THE POSTANTIBIOTIC EFFECTS OF CIPROFLOXACIN ON ESCHERICHIA-COLI, KLEBSIELLA-PNEUMONIAE, STAPHYLOCOCCUS-AUREUS AND STREPTOCOCCUS-PYOGENES [J].
HOWARD, BMA ;
PINNEY, RJ ;
SMITH, JT .
CHEMOTHERAPY, 1993, 39 (01) :22-31
[10]  
KUNIN CM, 1981, REV INFECT DIS, V3, P4